NCT01206335View on ClinicalTrials.gov

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
AnorexiaCancer Cachexia
Interventions
DRUG

OHR/AVR118

OHR/AVR118 given subcutaneously at 4mL per day

Trial Locations (1)

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

Sponsors
All Listed Sponsors
lead

Ohr Pharmaceutical Inc.

INDUSTRY